CBLL CERIBELL
Permanent stock page ↗Health Care · Russell 2000
Next earnings: not announced yet
What 9 analyst firms say about CERIBELL: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
8 rated views · 9 analyst/firm records · 9 firms
Radar score
- Russell 2000 · Top Picks · 6MBelow the Radar threshold of 8046
- Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8066
Recent analyst activity · last 90 days
Our tracked history has 11 reports on CBLL from 7 analyst firms in the last 90 days (9 firms in the past year).
Comparing each firm's latest target with its previous one: 1 raised its price target, 2 left it unchanged and 1 has its first observed target in the past year.
No firm's latest available rating differs from its previous one.
Latest observed target change: Canaccord Genuity raised its target from $26.00 (set 11 Aug 2026) to $33.00 on 4 Nov 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Barclays | Unnamed analyst | Hold | 18 Aug 2026 | — |
| BTIG | Marie Thibault | Buy | 11 Sep 2026 | 30.00 USD |
| Canaccord Genuity | William Plovanic | Buy | 11 Aug 2026 | 26.00 USD |
| Ladenburg Thalmann | Jeffrey S Cohen | Buy | 13 May 2026 | 32.00 USD |
| Raymond James | Jayson T Bedford | Buy | 11 Aug 2026 | 29.00 USD |
| TD Cowen | Joshua Jennings | Buy | 2 Oct 2026 | 33.00 USD |
| Weiss Ratings | Unnamed analyst | — | 16 Oct 2026 | — |
| William Blair | Brandon Vazquez | Buy | 11 Aug 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 06:15 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.